OptiBiotix Delivers Strong Growth and Tightens Focus on Profitability

OptiBiotix Health ( (GB:OPTI) ) has shared an update.

OptiBiotix Health reported a strong 2025 performance, with revenue up 30% to £1.13m, gross profit up 82% to £603,000 and margins rising to 53%, supported by stable operating costs and a cash balance of £1.03m. The company’s assets include holdings in ProBiotix Health and SkinBioTherapeutics valued at £6.45m at year-end, while product momentum was underlined by a Hydroxycut launch for SlimBiome and growing customer activity across Asia.

Post period, OptiBiotix has secured a 24-metric-tonne SlimBiome order from Taiwan’s Meelung Trading and logged over £800,000 of orders in January 2026, marking a record start to the year. Management is executing a strategic shift toward commercial sustainability, cutting marketing and R&D-related costs, improving SlimBiome production economics and imposing profit-and-loss discipline on regional and channel units, with the aim of achieving profitability across all parts of the business by the end of 2026.

The most recent analyst rating on (GB:OPTI) stock is a Hold with a £7.50 price target. To see the full list of analyst forecasts on OptiBiotix Health stock, see the GB:OPTI Stock Forecast page.

Spark’s Take on OPTI Stock

According to Spark, TipRanks’ AI Analyst, OPTI is a Neutral.

The score is weighed down primarily by persistent losses and cash burn despite strong 2024 revenue growth, and by weak technicals showing a sustained downtrend with negative momentum. A debt-free balance sheet provides some support, but valuation remains difficult to justify with negative earnings and no dividend yield provided.

To see Spark’s full report on OPTI stock, click here.

More about OptiBiotix Health

OptiBiotix Health is a UK-listed life sciences company focused on microbiome-based technologies that help prevent and manage human disease. It develops and commercialises prebiotic and functional ingredients such as SlimBiome, WellBiome, SweetBiotix and Microbiome Modulators, and also has exposure to skincare and probiotics through stakes in SkinBioTherapeutics and ProBiotix Health, serving weight management and gut health markets worldwide.

The group targets consumer health, weight management and metabolic wellness markets, supplying ingredients and finished products via international manufacturing, distribution and e-commerce channels. Its portfolio positions OptiBiotix in a fast-growing segment of healthcare where demand for scientifically supported microbiome solutions and healthier sugar substitutes is expanding in both developed and emerging markets.

Average Trading Volume: 522,480

Technical Sentiment Signal: Sell

Current Market Cap: £5.06M

See more data about OPTI stock on TipRanks’ Stock Analysis page.